Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Effect of Elotuzumab on Circulating Lymphocytes, Chemokines, and Cytokines In Multiple Myeloma Patients

Lauri Neyer, PhD, Han Ding, Doreen Chen, James P Sheridan, PhD, Audie Rice, PhD, Balaji Balasa, PhD, Steve Keller, PhD, Yuni Fang, PhD, Angie Albano, Ninian Tran, Vivian Zhao, Daniel EH Afar, PhD

Blood (2010) 116 (21): 4070.

https://doi.org/10.1182/blood.V116.21.4070.4070

Published: 2010

Journal Articles

CS-1 Is Expressed in Nasal Type NK/T Cell Lymphomas and Angioimmunoblastic T-Cell Lymphomas: Implications for Targeted Therapy with Elotuzumab (HuLuc63).

Eric D Hsi, MD, Roxanne Steinle, Balaji Balasa, Audie Rice, PhD, Young-Hyeh Ko, MD, Daniel E.H. Afar, PhD

Blood (2008) 112 (11): 1779.

https://doi.org/10.1182/blood.V112.11.1779.1779

Published: 2008

Journal Articles

Elotuzumab (HuLuc63) Activates CD56 dim Natural Killer Cells and Monocytes Resulting in the Release of IP-10 and MCP-1

Balaji Balasa, PhD, Mahrukh Huseni, MSc, Jyothi Cherukuri, MSc, Roxanne Steinle, BSc, Amulya Nanisetti, MSc, Daniel Afar, PhD, Eric Hsi, MD, Vladimir Vexler, PhD

Blood (2008) 112 (11): 108.

https://doi.org/10.1182/blood.V112.11.108.108

Published: 2008

Journal Articles

CS1: A Potential New Therapeutic Target for the Treatment of Multiple Myeloma.

Eric D. Hsi, MD, Roxanne Steinle, BA, Balaji Balasa, PhD, Aparna Draksharapu, MS, Benny Shum, MS, Marukh Huseni, BS, David Powers, PhD, Amulya Nanisetti, MS, Marna Williams, PhD, Vladimir Vexler, PhD, Mohamad Hussein, MD, Daniel Afar, PhD

Blood (2006) 108 (11): 3457.

https://doi.org/10.1182/blood.V108.11.3457.3457

Published: 2006

Journal Articles

CS1 Is Expressed on Myeloma Cells from Early Stage, Late Stage, and Drug-Treated Multiple Myeloma Patients, and Is Selectively Targeted by the HuLuc63 Antibody.

Susann Szmania, BS, Balaji Balasa, PhD, Priyangi Malaviarachchi, BS, Fenguhuang Zhan, MD,PhD, Yongsheng Huang, MS, Aparna Draksharapu, MD, Vladimir Vexler, PhD, John Shaughnessy, Jr., PhD, Bart Barlogie, MD,PhD, Guido Tricot, MD,PhD, Daniel Afar, PhD, van Rhee Frits, MD,PhD

Blood (2006) 108 (11): 660.

https://doi.org/10.1182/blood.V108.11.660.660

Published: 2006

NARROW

Effect of Elotuzumab on Circulating Lymphocytes, Chemokines, and Cytokines In Multiple Myeloma Patients

CS-1 Is Expressed in Nasal Type NK/T Cell Lymphomas and Angioimmunoblastic T-Cell Lymphomas: Implications for Targeted Therapy with Elotuzumab (HuLuc63).

Elotuzumab (HuLuc63) Activates CD56 dim Natural Killer Cells and Monocytes Resulting in the Release of IP-10 and MCP-1

CS1: A Potential New Therapeutic Target for the Treatment of Multiple Myeloma.

CS1 Is Expressed on Myeloma Cells from Early Stage, Late Stage, and Drug-Treated Multiple Myeloma Patients, and Is Selectively Targeted by the HuLuc63 Antibody.

Email alerts

ASH Publications

American Society of Hematology

Effect of Elotuzumab on Circulating Lymphocytes, Chemokines, and Cytokines In Multiple Myeloma Patients

CS-1 Is Expressed in Nasal Type NK/T Cell Lymphomas and Angioimmunoblastic T-Cell Lymphomas: Implications for Targeted Therapy with Elotuzumab (HuLuc63).

Elotuzumab (HuLuc63) Activates CD56 dim Natural Killer Cells and Monocytes Resulting in the Release of IP-10 and MCP-1

CS1: A Potential New Therapeutic Target for the Treatment of Multiple Myeloma.

CS1 Is Expressed on Myeloma Cells from Early Stage, Late Stage, and Drug-Treated Multiple Myeloma Patients, and Is Selectively Targeted by the HuLuc63 Antibody.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only